BLAINJECTIONINJECTABLE
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
5/8 — Partial
TRUXIMA (rituximab-abbs) by Celltrion is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2018.
Drug data last refreshed 3h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TRUXIMA (rituximab-abbs) is a CD20-directed monoclonal antibody biosimilar approved by FDA in November 2018 as a follow-on therapeutic equivalent to Rituxan. It works by binding to CD20 antigen on B cells, triggering cytolytic activity in hematologic malignancies and autoimmune conditions. This biosimilar targets the same mechanism as reference rituximab but offers potential cost advantages in a crowded competitive space.
$0.015BPart D
PeakAt peak commercial maturity with modest Part D spending ($15M), TRUXIMA is maintaining steady share in a mature CD20-inhibitor market; brand team size likely modest relative to originator competitors.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)
Started Jul 2022
60 enrolled
Lymphoma, Large B-Cell, Diffuse (DLBCL)
Career Relevance
TRUXIMA roles focus on commercial execution, payer negotiations, and market access in a commodity-pricing environment rather than innovation or clinical development. Career growth on this brand depends on contracting acumen, managed care relationships, and ability to compete on rebate/access terms rather than clinical differentiation.
Brand Manager
Worked on TRUXIMA at Celltrion? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.